Skip to main content
SpringerLink
Log in

Inside Story: Practical Experience with FQAD Patients

  • Chapter
  • First Online:
Fluoroquinolone-Associated Disability (FQAD) - Pathogenesis, Diagnostics, Therapy and Diagnostic Criteria

  • 297 Accesses

Abstract

In addition to the hard scientific data, there are a number of empirical values that can be important for the attending physician in dealing with FQAD.

Therefore, this chapter reports on many years of experience with now more than 500 FQAD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 19.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 29.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. FDA Drug Safety Communication. FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection Safety Announcement. 2013.

    Google Scholar 

  2. FDA/CDER Drug Information Webinar. “Fluoroquinolone-Associated Disability” (FQAD). April 4, 2017.

    Google Scholar 

  3. Marchant J. When antibiotics turn toxic. Nature News Feature; 21 Mar 2018.

    Google Scholar 

  4. Tachibana M, et al. Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes. Drug Metab Dispos. 2005;33:803–11. https://doi.org/10.1124/dmd.104.003178.

    Article  CAS  PubMed  Google Scholar 

  5. Mulhall JP, et al. Ciprofloxacin-induced acute psychosis. Urology. 1995;46(1):102–3. https://doi.org/10.1016/S0090-4295(99)80171-X.

    Article  CAS  PubMed  Google Scholar 

  6. Scavone C, et al. Quinolones-induced musculoskeletal, neurological, and psychiatric ADRs: a pharmacovigilance study based on data from the italian spontaneous reporting system. Front Pharmacol. 2020;11:428. https://doi.org/10.3389/fphar.2020.00428.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Rossi G, et al. Acute psychosis after treatment of epididymitis with ciprofloxacin. Cureus. 2018;10(5):e2605. https://doi.org/10.7759/cureus.2605.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Bhalerao S, et al. Ciprofloxacin-induced manic episode. Psychosomatics. 2006;47(6):539–40. https://doi.org/10.1176/appi.psy.47.6.539.

    Article  PubMed  Google Scholar 

  9. Mazhar F, et al. Moxifloxacin-induced acute psychosis: a case report with literature review. J Res Pharm Pract. 2016;5(4):294–6. https://doi.org/10.4103/2279-042X.192457.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Higdon E, et al. Moxifloxacin-induced visual hallucinations: a case report and review of the literature. J Pharm Pract. 2017;30(3):375–7. https://doi.org/10.1177/0897190016637987.

    Article  PubMed  Google Scholar 

  11. Steinert T, et al. Acute delusional parasitosis under treatment with ciprofloxacin. Pharmacopsychiatry. 2006 Jul;39(4):159–60. https://doi.org/10.1055/s-2006-947183.

    Article  CAS  PubMed  Google Scholar 

  12. Tomé A, et al. Quinolones: review of psychiatric and neurological adverse reactions. Drug Saf. 2011;34(6):465–88. https://doi.org/10.2165/11587280-000000000-00000.

    Article  PubMed  Google Scholar 

  13. Sahoo S, et al. Recurrent mania consequent to quinolones exposure: a case report and review of literature. J Family Med Prim Care. 2016;5(1):163–5. https://doi.org/10.4103/2249-4863.184654.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kommalapati A, et al. Fluoroquinolone-associated suicide. Eur J Intern Med. 2018;55:e21–2. https://doi.org/10.1016/j.ejim.2018.07.012.

    Article  PubMed  Google Scholar 

  15. Zareifopoulos N, et al. Neuropsychiatric effects of antimicrobial agents. Clin Drug Investig. 2017;37(5):423–37. https://doi.org/10.1007/s40261-017-0498-z.

    Article  CAS  PubMed  Google Scholar 

  16. Kaur K, et al. Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network. J Community Support Oncol. 2016;14(2):54–65. https://doi.org/10.12788/jcso.0167.

    Article  CAS  PubMed  Google Scholar 

  17. Schröder H, et al. Risikoreiche Verordnungen von Fluorchinolon-Antibiotika in Deutschland. Berlin: Wissenschaftliches Institut der AOK (WldO); 2019.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Konstanz, Baden-Württemberg, Germany

    Stefan Pieper

Authors
  1. Stefan Pieper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Pieper .

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pieper, S. (2021). Inside Story: Practical Experience with FQAD Patients. In: Fluoroquinolone-Associated Disability (FQAD) - Pathogenesis, Diagnostics, Therapy and Diagnostic Criteria . Springer, Cham. https://doi.org/10.1007/978-3-030-74173-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-74173-0_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-74172-3

  • Online ISBN: 978-3-030-74173-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation